Implementation of endometrial cancer molecular subtyping into a hybrid community-academic practice

CONCLUSIONS: Our protocol identified 22 (14%) of 157 LR tumors that harbored incipient intermediate- to high-risk molecular aberrations in TP53, CTNNB1, or L1CAM. Moving forward, results of ongoing trials assessing adjuvant therapy decisions based on molecular classification are necessary to confirm protocol utility and identify appropriate modifications.PMID:38430556 | DOI:10.1093/ajcp/aqae010

Source: American Journal of Clinical Pathology - March 2, 2024 Category: Pathology Authors: Elizabeth O Ferreira Alexandra M Schefter Abby Brustad Molly E Klein Mahmoud A Khalifa Boris Winterhoff Andrew C Nelson Source Type: research